MIST Milestone Pharma Earnings per share for the last twelve months

MIST (Milestone Pharmaceuticals Inc) - company brandmark

The 12-month net income per share trend for Milestone Pharmaceuticals (MIST) highlights the impact of mucosal delivery patents and Phase 3 trial costs. The value of -0.70 reflects the current metric level amid FDA approval risks for the nasal spray and reliance on external capital. Business stability is supported by the expanded application of the lead molecule and global licensing agreements.

Milestone Pharmaceuticals (MIST) - Earnings per share for the last four quarters from 07/04/2022 to 11/13/2026

Financial and market metric breakdowns for Milestone Pharmaceuticals, Inc. (MIST)

- stock price and consensus target price:
Stock Price Milestone Pharmaceuticals|MIST - Average Forecast Price
- market capitalization data:
Market Value Milestone Pharmaceuticals Inc.|MIST - Company Buyout Price
- shareholders' equity book value data:
Accounting Value per Share Milestone Pharmaceuticals|MIST - Total Net Assets|Market Value to Book Value Ratio milestonepharma.com|MIST - Company Assets
- issuer credit burden and liquidity indicators:
Debt to Equity Milestone Pharmaceuticals|MIST - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Milestone Pharma|MIST - Company Cumulative Debt|Debt to Book Value Milestone Pharmaceuticals Inc.|MIST - Company Long-Term Loans and Borrowings|Company Short-Term Debt Milestone Pharmaceuticals|Quick Ratio milestonepharma.com
- earnings and valuation multiples indicators:
MIST - Final Profit|Projected Future Earnings Milestone Pharmaceuticals|MIST - P/E Multiple|Future Price to Earnings Milestone Pharmaceuticals Inc.|MIST - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Milestone Pharmaceuticals Inc.|MIST - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Milestone Pharmaceuticals|MIST - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth milestonepharma.com|MIST - Net earnings per share growth this year|Earnings growth forecast for next year Milestone Pharmaceuticals
Basic company analysis:Milestone Pharmaceuticals - MIST
Mass-produced product of Milestone Pharmaceuticals, Inc.

Milestone Pharmaceuticals (MIST) is strengthening its position in emergency cardiology by integrating rhythm-control medications into clinical practice. By analyzing the company's rolling annual earnings per share, an investor can view the net income over 12 months divided by the number of shares, which allows for an assessment of real business efficiency without dilution distortions and helps determine the asset's fair value.

Competing companies

Regeneron Pharmaceuticals - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months irhythmtech.com|Lantheus (LNTH) - Earnings per share for the last twelve months|MLYS - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months HTFL|KMTS (Kestra Medical Corp) - Earnings per share for the last four quarters|Earnings per share for the last twelve months Esperion Therapeutics (ESPR)|AMRN - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Anteris Technologies AVR|TNYA: Earnings per share for the last 12 months|CVRx, Inc - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Cardiol Therapeutics|BEAT (HeartBeam, Inc.) - Net earnings per share for the last 12 months|tenaxthera.com - Earnings per share for the trailing year|Earnings per share for the last twelve months Adagio Medical|BioCardia Inc. - Earnings per one share for the last 12 months|Net earnings per share (EPS TTM) VTAK|ABIO (arcabio.com) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) ACST (Acasti Pharma Inc.)|Net earnings per share (EPS TTM) aerovatetx.com AVTE|VERV - Earnings per share for the last twelve months|Earnings per share for the trailing year WINT (Windtree Therapeutics)